Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: protease-activated monoclonal antibodies - Bristol-Myers Squibb/CytomX Therapeutics

Next Previous
Drug Profile

Research programme: protease-activated monoclonal antibodies - Bristol-Myers Squibb/CytomX Therapeutics

Alternative Names: CTX-023; CTX-033; CTX-1003; CX 188; CX 2005; EGFR Probody Drug Conjugate; J43 antibody; PD-1 probody therapeutic - CytomX Therapeutics; Probodies; Probody™ cancer therapeutics - Bristol-Myers Squibb

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytomX Therapeutics
  • Developer Bristol-Myers Squibb; CytomX Therapeutics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Epidermal growth factor receptor antagonists; Immunomodulators; Notch signalling pathway inhibitors; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Autoimmune disorders
  • Discontinued Inflammation

Most Recent Events

  • 11 Mar 2024 Preclinical development is still ongoing in Cancer in USA
  • 28 Dec 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 05 May 2021 CytomX Therapeutics withdraws the phase I PROCLAIM-CX-188 trial in Solid tumours in USA, prior to enrolment (NCT03706274)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top